Unless you are from another planet, you’ve heard all about the new weight loss medications taking the world by storm. These ...

Researchers have discovered that tirzepatide and semaglutide impact energy metabolism in distinct ways. New animal research ...

After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk ...

While some Ozempic faces are appearing older with sunken cheeks, gaunt eyes and sagging neck skin — that doesn’t seem to be ...

India's healthtech space is expected to witness disruption as weight loss drugs Ozempic and Mounjaro enter the market through ...

Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss copycats.

Manhattan-based dentist Dr. Sandip Sachar and obesity medicine specialist Dr. Meghan Garcia-Webb discuss the prevalence of ...

Inadequate supply has created opportunities for bad actors seeking to profit from shortages, high costs and demand ...

HHS Secretary Robert F. Kennedy Jr. told Fox’s Sean Hannity recently that he believes the Trump has lost 30 pounds.

Researchers found GLP-1s may modestly reduce the risk of 14 obesity-related cancers, especially colorectal cancer, when compared to a weight-neutral medication used to treat diabetes.

Dr. Rubinstein has years of experience working with patients to help them achieve their desired goals in a realistic, ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...